# Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

Study · id `cardio:ct-nct01728220` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01728220](<https://clinicaltrials.gov/study/NCT01728220>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01728220

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

## Technical summary

Registry record NCT01728220. Randomized; quadruple masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2014-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 159 participants (enrolled count; ClinicalTrials.gov record NCT01728220, source copy `cardio:ctgov-nct01728220-2023-02-27`, retrieved 2026-10-31)
- Start date: 2012-12 (registry gives no type) (ClinicalTrials.gov record NCT01728220, source copy `cardio:ctgov-nct01728220-2023-02-27`, retrieved 2026-10-31)
- Primary completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01728220, source copy `cardio:ctgov-nct01728220-2023-02-27`, retrieved 2026-10-31)
- Completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01728220, source copy `cardio:ctgov-nct01728220-2023-02-27`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01728220, source copy `cardio:ctgov-nct01728220-2023-02-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01728220-2023-02-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
- Condition: Pulmonary Hypertension
- Condition: Chronic Obstructive Pulmonary Disease
- Intervention (Combination product): Inhaled NO delivered via INOpulse DS-C Device
- Intervention (Combination product): Placebo delivered via INOpulse DS-C Device
- Lead sponsor: Bellerophon Pulse Technologies
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Bellerophon Pulse Technologies (`cardio:org-bellerophon-pulse-technologies`)

## Provenance

Content hash: 8135a840ee01dfcb31de94193687a50308d70a69afb5dcbb5c72f6d3e0572074
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
